Holen Sie sich die Stockscreener-App
24.55
2.67%
0.66
Schlusskurs vom Vortag:
$23.89
Offen:
$23.92
24-Stunden-Volumen:
1.38M
Relative Volume:
0.71
Marktkapitalisierung:
$4.06B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-451.71M
KGV:
-7.6098
EPS:
-3.2261
Netto-Cashflow:
$-462.19M
1W Leistung:
+3.32%
1M Leistung:
+20.65%
6M Leistung:
+36.26%
1J Leistung:
+165.45%
1-Tages-Spanne:
$23.70
$24.87
1-Wochen-Bereich:
$21.71
$24.87
52-Wochen-Spanne:
$8.88
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
24.55 | 3.95B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
480.00 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
665.67 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.09 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.74 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
275.34 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
DYN Initiated Coverage On by Cantor Fitzgerald -- Rating Set to Overweight - GuruFocus
Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway - The Globe and Mail
Dyne Therapeutics closes $431.4 million stock offering - Investing.com
Dyne Therapeutics closes $431.4 million stock offering By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Closing of Upsized Public - GlobeNewswire
Dyne a new overweight at Cantor on platform for neuromuscular disorders - Seeking Alpha
Cantor Fitzgerald initiates Dyne Therapeutics stock with overweight rating By Investing.com - Investing.com Canada
Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling? - Yahoo Finance
Form 424B5 Dyne Therapeutics Inc For: 22 July By Investing.com - Investing.com South Africa
Dyne Therapeutics Launches 18.3M-Share Offering at $20.50; Nets ~$352M, Greenshoe to $405M - TradingView
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) - MSN
Why Dyne Therapeutics (DYN) Stock Is Down Today - Moomoo
Dyne Therapeutics (DYN) Upsizes Public Offering to $375.15M Amid Stock Decline - GuruFocus
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - The Globe and Mail
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Why is Dyne Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Dyne Therapeutics stock falls 9% after pricing stock offering By Investing.com - Investing.com Australia
Dyne Therapeutics stock falls 9% after pricing stock offering - Investing.com UK
Dyne Therapeutics Prices Upsized $375.2 Million Secondary Offering - marketscreener.com
Form 424B5 Dyne Therapeutics Inc For: 21 July By Investing.com - Investing.com South Africa
Dyne Therapeutics Stock Tumbles After Hours: Here's Why - Benzinga
Form 424B5 Dyne Therapeutics Inc For: 21 July - Investing.com India
DYN: Increased Offering Size and Pricing Range Announced - GuruFocus
Dyne Therapeutics prices $375 million stock offering - Investing.com
Dyne Therapeutics prices $375 million stock offering By Investing.com - Investing.com South Africa
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock - The Manila Times
Dyne Therapeutics prices $375M upsized public o... - Pluang
Dyne Therapeutics,Announces Pricing Of Upsized Offering Of 18.3 Million Shares At $20.50 Per Share - TradingView
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock - GlobeNewswire Inc.
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits
Stocks to Watch: Super Micro Computer, AAR, Pegasystems, Dyne Therapeutics, Weatherford - Moomoo
Shares of Dyne Therapeutics Slide on $300M Stock Offering - Moomoo
Dyne Therapeutics Launches $300 Million Common Stock Offering - Moomoo
Dyne Therapeutics launches $300 million stock offering By Investing.com - Investing.com Nigeria
Dyne Therapeutics launches $300 million stock offering - Investing.com India
Dyne Therapeutics stock falls on $300M equity offering - Investing.com
Dyne Therapeutics Announces Proposed Public Offering of Common Stock - The Manila Times
Dyne Therapeutics stock falls on $300M equity offering By Investing.com - Investing.com Nigeria
Dyne Therapeutics Announces $300 Million Proposed Public Offering of Common Stock - Quiver Quantitative
Dyne Therapeutics Announces Proposed Public Offering Of Common Stock - TradingView
Press Release: Dyne Therapeutics Announces Proposed Public Offering of Common Stock - Moomoo
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dyne Therapeutics Inc-Aktie (DYN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rhodes Jason P | Director |
Jul 07 '26 |
Sale |
23.26 |
297,211 |
6,913,822 |
2,962 |
0.31%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):